Ardea Biosciences, Inc.
Ardea Biosciences Initiates a Phase 1/2 Study of RDEA119, its Lead MEK Inhibitor, in Combination with Nexavar sorafenib in Patients with Advanced Cancer
Published in Cancer Weekly, November 4th, 2008
Preclinical in-vitro and in-vivo studies of RDEA119 have demonstrated synergistic activity across multiple tumor types when RDEA119 is used in combination with other anti-cancer agents, including sorafenib. This Phase 1/2 study in patients with advanced cancer will evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2008-11-04)
More Articles from Cancer Weekly
- University of California - Santa Barbara
UCSB researchers develop cross-protective vaccine - Acceleron Pharma, Inc.
Celgene Corporation and Acceleron Pharma Initiate Phase 2 Study of ACE-011 in Patients with Multiple Myeloma - Breast Cancer
Brain Fitness Program Offers Hope for Breast Cancer Survivors Suffering From 'Chemobrain' - Cancer
Access Pharmaceuticals Presents ProLindac(TM) Data at the AACR-NCI-EORTC Symposium 2008 - Cancer Gene Therapy
Findings from N. Lecatguillet and co-researchers advance knowledge in cancer gene therapy - Cancer Vaccines
Investigators at Cork University release new data on cancer vaccines - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
